Patents by Inventor Zainuddin MOHD

Zainuddin MOHD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF
    Publication number: 20240246931
    Abstract: The present invention relates in general, to the field of pharmaceutical compounds, more particularly to the compounds of Formula (I) which acts as inhibitors for PD1/PD-L1 interaction. The present invention further relates to a method of preparation of compounds of Formula (I). The present invention also relates to a composition of compounds of Formula (I).
    Type: Application
    Filed: April 22, 2022
    Publication date: July 25, 2024
    Inventors: Naveen SADHU, Dhanalakshmi SIVANANDHAN, Zainuddin MOHD, Sridharan RAJAGOPAL
  • Heterocyclic compounds as PRMT5 inhibitors
    Patent number: 11459338
    Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: October 4, 2022
    Assignee: JUBILANT EPISCRIBE LLC
    Inventors: Saravanan Vadivelu, Sridharan Rajagopal, Raghunadha Reddy Burri, Shivani Garapaty, Dhanalakshmi Sivanandhan, Manish Kumar Thakur, Tamizharasan Natarajan, Indu N Swamy, Nagendra Nagaraju, Subramaniam Kanagaraj, Zainuddin Mohd, Sayantani Sarkar, Swapan Kumar Samanta, Hariprakash
  • HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
    Publication number: 20210371431
    Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
    Type: Application
    Filed: November 23, 2018
    Publication date: December 2, 2021
    Inventors: Saravanan VADIVELU, Sridharan RAJAGOPAL, Raghunadha Reddy BURRI, Shivani GARAPATY, Dhanalakshmi SIVANANDHAN, Manish Kumar THAKUR, Tamizharasan NATARAJAN, Indu N SWAMY, Nagendra NAGARAJU, Subramaniam KANAGARAJ, Zainuddin MOHD, Sayantani SARKAR, Swapan Kumar SAMANTA, Hariprakash N/A